Prof. Jianjun Han 韩建军
Chief Physician, Professor
Department of Interventional Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive and interventional treatments for liver cancer, liver metastases, lung cancer, brain tumors, and obstructive jaundice. Expertise includes tumor ablation and particle implantation.
Dr. Han is Director of the Interventional Department and a Professor. After earning a medical degree from Qingdao Medical College, Dr. Han completed a master’s in oncology (2004) and a PhD in general surgery oncology from Shandong University. A postdoctoral fellow at UNC Lineberger Comprehensive Cancer Center (2014–2015), Dr. Han focuses on minimally invasive tumor therapies and has published over 20 SCI papers.
Professional roles
- Chair, Shandong Medical Association Liver Tumor Branch
- Vice Chair, World Chinese Physicians Association Committee on Minimally Invasive and Interventional Oncology
- Vice Chair, China Anti-Cancer Association Tumor Intervention Professional Committee Ablation Expert Committee
- Member, Chinese Medical Association
Name order: in Chinese the family name comes first (Han Jianjun). Papers usually list the name as Jianjun Han or Han J.
Selected publications
52 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Endocrinol (Lausanne), 2026 (senior author): Metformin and atorvastatin ameliorate MASH via the AMPK/NF-κB pathway. PubMed 42935801
- Front Immunol, 2025 (senior author): Severe systemic cutaneous adverse reactions following camrelizumab therapy: a case report and literature review. PubMed 41488619
- Sci Rep, 2025 (senior author): Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway. PubMed 40790070
- Sci Rep, 2025 (senior author): Multiomics reveals metformin's dual role in gut microbiome remodeling and hepatic metabolic reprogramming for MAFLD intervention. PubMed 40594788
- Br J Cancer, 2025 (senior author): Correction: Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based study. PubMed 39900987
- Front Immunol, 2024 (senior author): Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients. PubMed 39439786
- Br J Cancer, 2024 (senior author): Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based study. PubMed 38971951
- Heliyon, 2024 (senior author): Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects. PubMed 39253229
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion